HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway.
Kuiyuan HuangZiying LiuZhanglian XieXiaoran LiHaixing ZhangYu ChenYiran WangZimo LinChuanjiang LiHongyan LiuXiaoyong ZhangPublished in: Journal of translational medicine (2023)
HIGD2A promoted liver cancer cell growth by fueling mitochondrial ATP synthesis and activating the MAPK/ERK pathway, suggested that targeting HIGD2A may represent a new strategy for HCC therapy.